Antinflammatory therapy and cardiovascular risk: A consensus view;Terapia antinfiammatoria e rischio cardiovascolare: Cosa fare?

Reumatismo

Volumn 58, Issue 2, 2006, Pages 85-93

  Gatti, Davide ^a   Adami, S ^b   Canesi, B ^b   Cimmino, Ma ^b   Della Casa, O ^b   Del Tacca, M ^b   Klersy, C ^c   Leardini, G ^b   Patrignani, P ^d   Punzi, L ^b   Bombardieri, S ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b Centro Studi SIR

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; ROFECOXIB; VALDECOXIB;

ADENOMATOUS POLYP; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; EDITORIAL; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; MEDICAL INFORMATION; MEDICAL RESEARCH; CHEMICALLY INDUCED DISORDER; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS;

EID: 34249046390     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (48)

1. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antinflammatory drugs. N Engl J Med 1999; 340: 1888-99.
2. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999; 96: 272-7.
3. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L,et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735-41.
4. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med 2000; 343: 1520-8.
5. Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, et al. Clinical pharmacology of platelet monocyte and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004; 109; 1468-71.
6. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Eng J Med 2001; 345: 1809-17.
7. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002; 162: 1111-5.
8. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162: 1105-10.
9. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. and the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigations: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
10. Solomon SD, McMurray JV, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. and the Adenoma Prevention on Celecoxib (APC) Study Investigators; Cardiovascular events associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-80.
11. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al; Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J of Med 2005; 352: 1081-91.
12. Wayne AR, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-73.
13. FDA statement ://www.fda.gov/bbs/ topics/news/2004/NEW01144.html
14. Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of antihypertensive treatment during nonsteroidal antinflammatory drug therapy. JAMA 1994; 272: 781-6.
15. Pope JL, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153: 477-84.
16. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgecis dose and risk of incident hypertension in US women. Hypertension 2005; 46: 500-7.
17. FitzGerald GA, PAtrono C. The coxib selective inhibitors of cyclooxygenase-2. New Engl J Med 2001; 345: 433-42.
18. Curham GC, Willett WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 2002; 162: 2204-08.
19. Sciulli MG, Seta F, Tacconelli S, Capone ML, Ricciotti E, Pistritto G, et al. Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells. Br J Pharmacol 2003;138: 634-41.
20. Walter MF, Jacob RF, Day CA, Dahlborg R, Weng Y, Mason RP. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulphonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004; 177: 235-43.
21. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression and gene chromosomal assignement. FASEB J 1991; 5: 2304-12.
22. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet tromboxane production by low-dose aspeirin in healthy subjects. J Clin Invest 1982; 69:1366-72.
23. Patrono C, Coller B, Fitzgerald GA, Hirsh J, Roth G. Platelet -active drugs: the relationship among dose, effectiveness and side effects. Chest 2004; 126: 234S-264S.
24. Pedersen AK, FitzGerald GA. Cyclooxygenase inhibition platelet function and metabolite formation durino chronic sulfinpyrazone dosing. Clin Pharmacol Ther 1985; 35; 209-21.
25. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non aspirin nonsteroidal antinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000; 11: 382-7.
26. Rao GH, Johnson GG, Reddy KR, White JG. Ibuprofen protects platelet cyclooxygenase from irreversibile inhibition by aspirin. Arterioslerosis 1983; 3; 383-8
27. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-4.
28. Hudson M, Baron M, Rahme E, Pilote L. Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. J Rheumatol 2005; 32: 1589-93.
29. Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005; 45: 1295-301.
30. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) reduction in ulcer complications: randomised controlled trial. Lancet 2004; 363: 665-74.
31. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-84
32. Baraf HSB, Fuentealba C, Greenwald M, Brzezicki J, O'Brien K, et al. Tolerability and effectiveness of etoricoxib compared to diclofenac sodium in patients with osteoarthritis: a randomized controlled study (EDGE trial). Arthritis and Rheumatism 2004; 50 (Suppl): 346-47.
33. Capone ML, Tacconelli S, Patrignani P. Clinical Pharmacology of etoricoxib. Expert Opin Drug Metab Toxicol 2005; 1: 269-82.
34. FDA statement ://www.fda.gov/bbs/topics/news/2004/NEW01148.html.
35. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs:population based nested case-control analysis. BMJ 2005; 330: 1366-77
36. Sudbo J, Lee JJ, Lippman S M, Mork J, Sagen S, Flatner N, et al. Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. Lancet 2005; 366: 1359-66.
37. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Jama 2000; 284: 1247-55.
38. Pfizer Inc News Release. Pfizer statement on new information regarding cardiovascular safety of Celebrex [17 December]. [Press release] 2004 [accessed 21 November 2005]; Available from: http://www.pfizer.com/pfizer/are/ investors_releases/2004pr/mn_2004_1217.jsp
39. Pfizer. A double-blind randomized placebo-controlled comparative study of celecoxib (SC-58635) for the inhibition of progression of Alzheimer's disease, protocol IQ5-97-02-001. 2000 [accessed 21 November 2005 2005]; Available from: http://www.clinicalstudyresults.org/documents/company-study_76_0.pdf.
40. Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125: 1481-92.
41. US Department of Health and Human Services. Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer's disease prevention trial. NIH News 2004 [accessed 21 November 2005]; Available from: http://www.nih.gov/ news/pr/dec2004/od-20.htm.
42. Pfizer Inc News Release. Pfizer says new NIH study results are consistent with large body of evidence supporting cardiovascular safety of Celebrex [21 December]. 2004 [accessed 21 November 2005]; Available from: http://www.pfizer.com/pfizer/are/news_releases/2004pr/mn_2004_1221.jsp.
43. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-3.
44. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction. Arch Intern Med 2003; 163: 481-6.
45. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, et al. Relationship between selective COX-2 inhibitors and acute myocardial infarction. Circulation 2004; 109: 2068-73.
46. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and nonselective non-steroidal anti-inflammatory drugs: nested casecontrol. study. Lancet 2005; 365: 475-81
47. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142157-64.
48. Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins CD. Selective cyclooxygenase-2 inhibition and cardiovascular effects. Arch Intern Med 2005; 165: 181-6.